Literature DB >> 29989135

The role of surface charge in the interaction of nanoparticles with model pulmonary surfactants.

F Mousseau1, J-F Berret.   

Abstract

Inhaled nanoparticles traveling through the airways are able to reach the respiratory zone of the lungs. In such an event, the incoming particles first come into contact with the liquid lining the alveolar epithelium, the pulmonary surfactant. The pulmonary surfactant is composed of lipids and proteins that are assembled into large vesicular structures. The question of the nature of the biophysicochemical interaction with the pulmonary surfactant is central to understand how the nanoparticles can cross the air-blood barrier. Here we explore the phase behavior of sub-100 nm particles and surfactant substitutes under controlled conditions. Three types of surfactant mimetics, including the exogenous substitute Curosurf®, a drug administered to infants with respiratory distress syndrome, are tested together with aluminum oxide (Al2O3), silicon dioxide (SiO2) and polymer (latex) nanoparticles. The main result here is the observation of spontaneous nanoparticle-vesicle aggregation induced by coulombic attraction. The role of the surface charges is clearly established. We also evaluate the supported lipid bilayer formation recently predicted and find that in the cases studied these structures do not occur. Pertaining to the aggregate internal structure, fluorescence microscopy shows that the vesicles and particles are intermixed at the nano- to microscale. With particles acting as stickers between vesicles, it is anticipated that the presence of inhaled nanomaterials in the alveolar spaces could significantly modify the interfacial and bulk properties of the pulmonary surfactant and interfere with lung physiology.

Entities:  

Year:  2018        PMID: 29989135     DOI: 10.1039/c8sm00925b

Source DB:  PubMed          Journal:  Soft Matter        ISSN: 1744-683X            Impact factor:   3.679


  6 in total

1.  Bioinspired particle engineering for non-invasive inhaled drug delivery to the lungs.

Authors:  Snehal K Shukla; Apoorva Sarode; Dipti D Kanabar; Aaron Muth; Nitesh K Kunda; Samir Mitragotri; Vivek Gupta
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2021-07-15

2.  Lung surfactant negatively affects the photodynamic inactivation of bacteria-in vitro and molecular dynamic simulation analyses.

Authors:  Giulia Kassab; Johan Sebastian Diaz Tovar; Lucas Miguel Pereira Souza; Rayla Kelly Magalhães Costa; Rudielson Santos Silva; André Silva Pimentel; Cristina Kurachi; Vanderlei Salvador Bagnato
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-13       Impact factor: 12.779

Review 3.  Application of nanotechnology in drug delivery systems for respiratory diseases (Review).

Authors:  Ming-Xin Luo; Shan Hua; Qi-Yun Shang
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

4.  Revealing the pulmonary surfactant corona on silica nanoparticles by cryo-transmission electron microscopy.

Authors:  Fanny Mousseau; Evdokia K Oikonomou; Annie Vacher; Marc Airiau; Stéphane Mornet; Jean-François Berret
Journal:  Nanoscale Adv       Date:  2020-01-07

Review 5.  Interactions of particulate matter and pulmonary surfactant: Implications for human health.

Authors:  Feifei Wang; Jifang Liu; Hongbo Zeng
Journal:  Adv Colloid Interface Sci       Date:  2020-08-19       Impact factor: 12.984

6.  Pulmonary surfactant inhibition of nanoparticle uptake by alveolar epithelial cells.

Authors:  M Radiom; M Sarkis; O Brookes; E K Oikonomou; A Baeza-Squiban; J-F Berret
Journal:  Sci Rep       Date:  2020-11-10       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.